Regulatory FDA approves Enhertu for two HER2-positive early breast cancer indications Pharmaceutical TechnologyThe FDA has approved Daiichi Sankyo and AstraZeneca's Enhertu for two new indications in HER2-positive early breast cancer.OncologyRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaceutical Technology The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer. Oncology Read full story Post navigation Previous: Arna Pharma and Slate Run complete JV for new US companyNext: Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026